Molecular Assemblies, a leader in enzymatic DNA synthesis, has received an additional $4 million from DARPA to further develop its technology for on-demand DNA vaccine manufacturing. The company’s Fully Enzymatic Synthesis (FES) technology is being used in the DARPA NOW project to create a mobile platform for rapid production of DNA-based vaccines and therapeutics anywhere in the world.
In the rapidly growing field of DNA synthesis, a variety of methods are available to produce synthetic DNA for applications in pharmaceuticals, therapeutics, and research. Chemical synthesis, a well-established method, offers versatility and cost-effectiveness. Enzymatic DNA synthesis, a newer method, promises efficiency and sustainability. Both methods have their strengths and weaknesses, and the choice between them depends on specific project requirements.
Chemical synthesis uses chemical reagents to build DNA molecules, allowing for the incorporation of various modifications. Enzymatic synthesis utilizes enzymes to synthesize DNA more efficiently, but it faces challenges in selectivity and cost.
As the demand for DNA synthesis surges, both chemical and enzymatic methods are evolving to improve efficiency and sustainability. Collaboration between biopharmaceutical innovators and DNA synthesis providers is crucial to optimize DNA synthesis for specific projects.
Ultimately, the choice between chemical and enzymatic DNA synthesis should be based on a thorough understanding of the project’s requirements and a partnership with experienced DNA synthesis providers.
